RiverPark Advisors’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.88M Buy
+264,866
New +$2.85M 1.25% 25

Other funds holding DMAA

RiverPark Advisors's DMAA Position: Q3 2026 in Review

RiverPark Advisors opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q3 2026: 264,866 shares worth $2.88M. The stake represents 1.25% of the portfolio and ranks #25 among its holdings.

23 funds tracked by Wall St. Rank hold DMAA as of Q3 2026.

  • RiverPark Advisors held 264,866 shares of Drugs Made In America Acquisition Corp worth $2.88M as of Q3 2026.
  • Drugs Made In America Acquisition Corp was a new RiverPark Advisors position in Q3 2026.
  • Drugs Made In America Acquisition Corp made up 1.25% of RiverPark Advisors's portfolio in Q3 2026, its #25 holding.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2026.

Based on RiverPark Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.